Advertisement

Intensive Care Medicine

, Volume 44, Issue 12, pp 2302–2304 | Cite as

New molecular semi-quantification tool provides reliable microbiological evidence for pulmonary infection

  • Javier Yugueros-Marcos
  • Olivier Barraud
  • Alexandra Iannello
  • Marie Cécile Ploy
  • Christine Ginocchio
  • Margarita Rogatcheva
  • Cristina Alberti-Segui
  • Alexandre Pachot
  • Virginie Moucadel
  • Bruno François
  • For the VALIBI study group
Letter

Dear Editor,

Ventilator-associated pneumonia (VAP) remains one of the most commonly encountered hospital-acquired infections worldwide, despite recent national surveillance data suggesting its declining incidence [1]. Many reports have been published on the use of large multiplex rapid diagnostic methods for various community-acquired infections, but their validity for the microbiological diagnosis of VAP using a semi-quantitative approach has not yet been assessed [2, 3].

Bronchoalveolar lavage (BAL) specimens from a prospective, non-randomized, non-interventional, multicenter clinical trial enrolling 120 patients [4] were used to evaluate the new BioFire®Pneumonia Panel (BPP). A total of 117 BAL specimens were tested with the BPP, which enabled the detection of 18 bacteria, 8 viruses, and 7 antimicrobial resistance-associated genes in 1 h. Results were compared with conventional culture methods (CC). Assessment of concordance for the identification of 15 commonly detected bacteria...

Notes

Acknowledgements

The authors gratefully acknowledge the VALIBI study group for their contribution to the VALIBI clinical study. The authors thank Isabelle Herafa from Inserm CIC 1435, Marc Clavel from CHU Limoges, and Marie-Astrid Jestin from bioMérieux for managing operations during the whole clinical study. The authors would like to thank Isabelle Sothier, Coralie Heyd, Caroline Dubost, Christelle Weber, and Rehane Ottaviani for their invaluable technical support running samples and carrying out investigations into discrepancies. The authors would like to thank Julien Textoris and Mark Miller for their thorough manuscript review and help in summarizing observations from this study. Funding was provided by bioMérieux S.A. and was part of ADNA (Advanced Diagnostic for New Therapeutic Approaches), a program dedicated to personalized medicine, coordinated by the Institut Mérieux and supported by the French public agency BPI France. The VALIBI study group members are: Limoges: Marc Clavel, Nicolas Pichon, Philippe Vignon, Roselyne Droual, Cécile Duchiron, Julie Vignaud, Delphine Chainier. Brive: Elias Karam, Mathieu Mattei, André Sommabere. Tours: Emmanuelle Mercier, Cécile Le Brun. Angoulême: Arnaud Desachy, Caroline Garandeau. bioMérieux: Marc Rodrigue, Morgane Lacroix, Sandrine Prudent, Marie-Astrid Jestin.

Compliance with ethical standards

Conflicts of interest

BF, OB, and MCP institutions have received funding from bioMérieux to run the VALIBI study. JYM, AI, CAS, AP, and VM are employees of bioMérieux. S.A. CG is an employee of bioMérieux Inc. MR is an employee of BioFire Diagnostics LLC.

References

  1. 1.
    Wang Y, Eldridge N, Metersky ML, Verzier NR, Meehan TP, Pandolfi MM, Foody JM, Ho SY, Galusha D, Kliman RE, Sonnenfeld N, Krumholz HM, Battles J (2014) National trends in patient safety for four common conditions, 2005–2011. N Eng J Med 370:341–351CrossRefGoogle Scholar
  2. 2.
    Ramanan P, Bryson AL, Binnicker MJ, Pritt BS, Patel R (2017) Syndromic panel-based testing in clinical microbiology. Clin Microbiol Rev 31:pii:e00024-17CrossRefGoogle Scholar
  3. 3.
    Jamal W, Al Roomi E, AbdulAziz LR, Rotimi VO (2014) Evaluation of Curetis Unyvero, a multiplex PCR-based testing system, for rapid detection of bacteria and antibiotic resistance and impact of the assay on management of severe nosocomial pneumonia. J Clin Microbiol 52:2487–2492CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Clavel M, Barraud O, Moucadel V, Meynier F, Karam E, Ploy MC, Francois B (2016) Molecular quantification of bacteria from respiratory samples in patients with suspected ventilator-associated pneumonia. Clin Microbiol Infect 22:812.e1–812.e7CrossRefGoogle Scholar
  5. 5.
    Jourdain B, Joly-Guillou ML, Dombret MC, Calvat S, Trouillet JL, Gibert C, Chastre J (1997) Usefulness of quantitative cultures of BAL fluid for diagnosing nosocomial pneumonia in ventilated patients. Chest 111:411–418CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature and ESICM 2018

Authors and Affiliations

  • Javier Yugueros-Marcos
    • 1
    • 2
  • Olivier Barraud
    • 3
  • Alexandra Iannello
    • 1
  • Marie Cécile Ploy
    • 3
  • Christine Ginocchio
    • 4
    • 5
  • Margarita Rogatcheva
    • 4
  • Cristina Alberti-Segui
    • 2
  • Alexandre Pachot
    • 1
  • Virginie Moucadel
    • 1
  • Bruno François
    • 3
    • 6
    • 7
  • For the VALIBI study group
  1. 1.Medical Diagnostic Discovery Department (MD3)bioMérieux S.A.GrenobleFrance
  2. 2.bioMérieux S.A./BioFire LLC Research and DevelopmentGrenobleFrance
  3. 3.Univ. Limoges, Inserm, CHU Limoges, RESINFIT, U1092LimogesFrance
  4. 4.BioFire Diagnostics, LLCSalt Lake CityUSA
  5. 5.bioMérieux Inc.DurhamUSA
  6. 6.Réanimation PolyvalenteCHU DupuytrenLimogesFrance
  7. 7.Inserm CIC1435CHU DupuytrenLimogesFrance

Personalised recommendations